Liraglutide Audit ADA San Francisco 2014 - Poster

Combined liraglutide-insulin therapy is associated with metabolic improvement and insulin dose reduction in commonly prescribed insulin regimens

Piya Sen Gupta1, Ken Y Thong2, Christopher Walton3, Robert EJ Ryder1, on behalf of ABCD liraglutide audit contributors

1City Hospital, Birmingham, UK

2Rockingham General Hospital, Perth, Australia

3Hull Royal Infirmary, Hull, UK

Discipline

Diabetes
Resource taxonomy
Audit Posters
Clinical taxonomy
Treatments for diabetes Type 2 diabetes mellitus
Listing status
Archived

ABCD Corporate Pharma Sponsors

Gold

  • AstraZeneca UK
  • Boehringer Ingelheim and Lilly Alliance
  • Eli Lilly and Company

Silver

  • A Menarini Farmaceutica Internazionale SRL
  • Sanofi

ABCD Corporate Pump & Device Sponsors

Gold

  • Abbott
  • Dexcom
  • Ypsomed Ltd

Silver

  • Air Liquide Healthcare Ltd
  • Insulet International
  • Medtronic Limited

Contact

Address for correspondence: 
ABCD (Diabetes Care) Ltd, 483 Green Lanes, London, N13 4BS

Telephone: 01675 477602
Email: info@abcd.care

Follow Us

ABCD (Diabetes Care) is a company limited by shares in England and Wales under company number 7270377, whose registered address is 3rd Floor, 56 Wellington Street. Leeds, LS1 2EE  Diabetes Care Trust (ABCD) is a registered charity number 1139057, a company limited by guarantee in England and Wales under company number 74248361,whose registered address is 3rd Floor, 56 Wellington Street. Leeds, LS1 2EE . ABCD (Diabetes Care) Ltd is a wholly owned subsidiary of the Diabetes Care Trust (ABCD) Ltd